Co-crystals of diflunisal and isomeric pyridinecarboxamides - a thermodynamics and crystal engineering contribution

Diflunisal is an anti-inflammatory, non-steroidal drug, class II of the Biopharmaceutical Classification System, which has recently been the subject of renewed interest due to its potential for use in the oral therapy of familial amyloid polyneuropathy. In this study, a thermodynamics based approach...

Full description

Saved in:
Bibliographic Details
Published inCrystEngComm Vol. 18; no. 25; pp. 4749 - 4759
Main Authors Évora, António O. L, Castro, Ricardo A. E, Maria, Teresa M. R, Silva, M. Ramos, ter Horst, J. H, Canotilho, João, Eusébio, M. Ermelinda S
Format Journal Article
LanguageEnglish
Published 01.01.2016
Subjects
Online AccessGet full text
ISSN1466-8033
1466-8033
DOI10.1039/c6ce00380j

Cover

Abstract Diflunisal is an anti-inflammatory, non-steroidal drug, class II of the Biopharmaceutical Classification System, which has recently been the subject of renewed interest due to its potential for use in the oral therapy of familial amyloid polyneuropathy. In this study, a thermodynamics based approach is used to investigate binary mixtures (diflunisal + picolinamide and diflunisal + isonicotinamide) in order to identify solid forms that are potentially useful to improve the biopharmaceutical performance of this active pharmaceutical ingredient. Special emphasis is placed on the research of co-crystals and on the influence of structural changes in the pyridinecarboxamide co-former molecules for co-crystal formation with diflunisal. The thermodynamics based methodology described by ter Horst et al. in 2010 indicates that the formation of co-crystals is thermodynamically feasible for both systems. The binary solid-liquid phase diagrams were built and allowed unequivocal identification of the formation of co-crystals of diflunisal with each of the two isomers and also their stoichiometry of 1 : 1, (diflunisal : co-former) in the case of pyridine-2-carboxamide (picolinamide) and (2 : 1) for pyridine-4-carboxamide (isonicotinamide). Two binary eutectic mixtures, potentially relevant for pharmaceutical application, were also identified. Infrared spectroscopy allowed the identification of the acid N-pyridine heterosynthon in the three co-crystals formed by diflunisal with the isomeric pyridinecarboxamides. However, the results clearly differentiated pyridine-2-carboxamide from pyridine-3-carboxamide and pyridine-4-carboxamide, that share similar crystalline arrangements, at least with respect to the supramolecular synthons. A thermodynamics based investigation of diflunisal + picolinamide and diflunisal + isonicotinamide binary mixtures is presented. The influence of structural changes of pyridinecarboxamides in co-crystal formation is addressed.
AbstractList Diflunisal is an anti-inflammatory, non-steroidal drug, class II of the Biopharmaceutical Classification System, which has recently been the subject of renewed interest due to its potential for use in the oral therapy of familial amyloid polyneuropathy. In this study, a thermodynamics based approach is used to investigate binary mixtures (diflunisal + picolinamide and diflunisal + isonicotinamide) in order to identify solid forms that are potentially useful to improve the biopharmaceutical performance of this active pharmaceutical ingredient. Special emphasis is placed on the research of co-crystals and on the influence of structural changes in the pyridinecarboxamide co-former molecules for co-crystal formation with diflunisal. The thermodynamics based methodology described by ter Horst et al. in 2010 indicates that the formation of co-crystals is thermodynamically feasible for both systems. The binary solid-liquid phase diagrams were built and allowed unequivocal identification of the formation of co-crystals of diflunisal with each of the two isomers and also their stoichiometry of 1 : 1, (diflunisal : co-former) in the case of pyridine-2-carboxamide (picolinamide) and (2 : 1) for pyridine-4-carboxamide (isonicotinamide). Two binary eutectic mixtures, potentially relevant for pharmaceutical application, were also identified. Infrared spectroscopy allowed the identification of the acid N-pyridine heterosynthon in the three co-crystals formed by diflunisal with the isomeric pyridinecarboxamides. However, the results clearly differentiated pyridine-2-carboxamide from pyridine-3-carboxamide and pyridine-4-carboxamide, that share similar crystalline arrangements, at least with respect to the supramolecular synthons. A thermodynamics based investigation of diflunisal + picolinamide and diflunisal + isonicotinamide binary mixtures is presented. The influence of structural changes of pyridinecarboxamides in co-crystal formation is addressed.
Diflunisal is an anti-inflammatory, non-steroidal drug, class II of the Biopharmaceutical Classification System, which has recently been the subject of renewed interest due to its potential for use in the oral therapy of familial amyloid polyneuropathy. In this study, a thermodynamics based approach is used to investigate binary mixtures (diflunisal + picolinamide and diflunisal + isonicotinamide) in order to identify solid forms that are potentially useful to improve the biopharmaceutical performance of this active pharmaceutical ingredient. Special emphasis is placed on the research of co-crystals and on the influence of structural changes in the pyridinecarboxamide co-former molecules for co-crystal formation with diflunisal. The thermodynamics based methodology described by ter Horst et al.in 2010 indicates that the formation of co-crystals is thermodynamically feasible for both systems. The binary solid-liquid phase diagrams were built and allowed unequivocal identification of the formation of co-crystals of diflunisal with each of the two isomers and also their stoichiometry of 1 : 1, (diflunisal : co-former) in the case of pyridine-2-carboxamide (picolinamide) and (2 : 1) for pyridine-4-carboxamide (isonicotinamide). Two binary eutectic mixtures, potentially relevant for pharmaceutical application, were also identified. Infrared spectroscopy allowed the identification of the acid...N-pyridine heterosynthon in the three co-crystals formed by diflunisal with the isomeric pyridinecarboxamides. However, the results clearly differentiated pyridine-2-carboxamide from pyridine-3-carboxamide and pyridine-4-carboxamide, that share similar crystalline arrangements, at least with respect to the supramolecular synthons.
Author Castro, Ricardo A. E
Eusébio, M. Ermelinda S
Maria, Teresa M. R
Silva, M. Ramos
Canotilho, João
Évora, António O. L
ter Horst, J. H
AuthorAffiliation Department of Chemistry
University of Coimbra
Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS)
EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation (CMAC)
University of Strathclyde
Technology and Innovation Centre
Faculty of Pharmacy
Department of Physics
AuthorAffiliation_xml – sequence: 0
  name: Faculty of Pharmacy
– sequence: 0
  name: Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS)
– sequence: 0
  name: Department of Chemistry
– sequence: 0
  name: Department of Physics
– sequence: 0
  name: University of Strathclyde
– sequence: 0
  name: EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation (CMAC)
– sequence: 0
  name: Technology and Innovation Centre
– sequence: 0
  name: University of Coimbra
Author_xml – sequence: 1
  givenname: António O. L
  surname: Évora
  fullname: Évora, António O. L
– sequence: 2
  givenname: Ricardo A. E
  surname: Castro
  fullname: Castro, Ricardo A. E
– sequence: 3
  givenname: Teresa M. R
  surname: Maria
  fullname: Maria, Teresa M. R
– sequence: 4
  givenname: M. Ramos
  surname: Silva
  fullname: Silva, M. Ramos
– sequence: 5
  givenname: J. H
  surname: ter Horst
  fullname: ter Horst, J. H
– sequence: 6
  givenname: João
  surname: Canotilho
  fullname: Canotilho, João
– sequence: 7
  givenname: M. Ermelinda S
  surname: Eusébio
  fullname: Eusébio, M. Ermelinda S
BookMark eNptkctLxDAQxoMouLt68S7kKEI1j222PUpZXyx40XNJp9M1S5usSRfsf2_2gYp4mpnw_b4h34zJsXUWCbng7IYzmd-CAmRMZmx1REZ8qlSSMSmPf_WnZBzCijE-5ZyNSChcAn4IvW4DdQ2tTdNurAm6pdrW1ATXoTdA14M3tbEI2lfuU3emxkATqmn_jr5z9WDjG4QddPCjaJeRiLhdUnC296ba9MbZM3LSxHV4fqgT8nY_fy0ek8XLw1Nxt0hACtknyMVMIFR1o6dK5lwhVwCsSRsUkDM-Y6molah0HDKdpbwSiuWzmECWZ1poOSFXe9-1dx8bDH3ZmQDYttqi24SSZyJNuRIij9LrvRS8C8FjU6696bQfSs7KbbJloYr5LtnnKGZ_xGB6vf1Z77Vp_0cu94gP8G39cyz5BcdxiWQ
CitedBy_id crossref_primary_10_1016_j_ijpharm_2021_120605
crossref_primary_10_1016_j_ejps_2019_01_007
crossref_primary_10_1002_chem_201904130
crossref_primary_10_3390_cryst9020070
crossref_primary_10_1016_j_ijpharm_2024_124959
crossref_primary_10_3390_pharmaceutics12111098
crossref_primary_10_2174_1381612826666200523173448
crossref_primary_10_1007_s10973_017_6474_2
crossref_primary_10_1016_j_ijpharm_2021_120441
crossref_primary_10_1021_acs_cgd_6b01154
crossref_primary_10_3390_pharmaceutics13122081
crossref_primary_10_1016_j_partic_2021_03_015
crossref_primary_10_1039_C6CE01835A
Cites_doi 10.1039/J19660000439
10.1021/cg800173d
10.1039/C4CE00265B
10.1002/jps.21280
10.1107/S0365110X66003396
10.1016/j.molstruc.2003.07.010
10.1021/mp0600182
10.1039/b818268j
10.1021/cg701024c
10.1039/c2ce26244d
10.1039/b313552g
10.1039/C5CC08216A
10.1039/b402150a
10.1039/C0CC04117C
10.1107/S0021889810054725
10.1039/B612353H
10.1351/pac200678071455
10.1021/cg2009946
10.1039/c2cc18025a
10.1021/op400182k
10.1016/S1056-8719(00)00107-6
10.1002/jps.23402
10.1021/cg025593z
10.1002/anie.201302814
10.1021/cg901230b
10.1002/jps.22234
10.1039/c3ce40286j
10.1039/b315687g
10.1080/01496399508010394
10.3109/13506129.2012.678509
10.1021/cg025589n
10.1021/cg801200h
10.1016/S0378-5173(00)00505-6
10.1021/jp101303j
10.1071/CH05270
10.1007/s11095-006-9032-3
10.1021/cg070218y
10.1039/b708112j
10.1021/cg200288b
10.1016/j.ejps.2014.06.017
10.1039/C3CC47521B
10.1016/j.ijpharm.2014.02.048
10.1039/c1ce06320k
10.1039/a806387g
10.1039/c3ce41013g
10.1039/c2ce06391c
10.1016/0040-6031(90)80235-Q
10.1016/0040-6031(95)02717-3
10.1002/jps.20578
ContentType Journal Article
DBID AAYXX
CITATION
7U5
8FD
L7M
DOI 10.1039/c6ce00380j
DatabaseName CrossRef
Solid State and Superconductivity Abstracts
Technology Research Database
Advanced Technologies Database with Aerospace
DatabaseTitle CrossRef
Technology Research Database
Advanced Technologies Database with Aerospace
Solid State and Superconductivity Abstracts
DatabaseTitleList
Technology Research Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 1466-8033
EndPage 4759
ExternalDocumentID 10_1039_C6CE00380J
c6ce00380j
GroupedDBID -JG
0-7
0R~
29F
4.4
5GY
6J9
705
70~
7~J
AAEMU
AAIWI
AAJAE
AAMEH
AANOJ
AAWGC
AAXHV
AAXPP
ABASK
ABDVN
ABEMK
ABJNI
ABPDG
ABRYZ
ABXOH
ACGFO
ACGFS
ACLDK
ADMRA
ADSRN
AEFDR
AENEX
AENGV
AESAV
AETIL
AFLYV
AFOGI
AFVBQ
AGEGJ
AGKEF
AGRSR
AGSTE
AHGCF
ALMA_UNASSIGNED_HOLDINGS
ANBJS
ANUXI
APEMP
ASKNT
AUDPV
AZFZN
BLAPV
BSQNT
C6K
CS3
E3Z
EBS
ECGLT
EE0
EF-
EJD
GGIMP
GNO
H13
HZ~
H~N
IDZ
J3I
N9A
O9-
OK1
P2P
R7B
RAOCF
RCNCU
RNS
ROL
RPMJG
RRA
RRC
RSCEA
SKA
SLH
VH6
0UZ
1TJ
71~
AAYXX
ACHDF
ACRPL
ADNMO
AFRZK
AGQPQ
AHGXI
AKMSF
ALSGL
ANLMG
ASPBG
AVWKF
BBWZM
CAG
CITATION
COF
EEHRC
FEDTE
HVGLF
IDY
J3G
J3H
L-8
M4U
NDZJH
R56
RCLXC
7U5
8FD
L7M
ID FETCH-LOGICAL-c323t-e1272ecbdfa463916e16cc0f5fe2c9017052d62bac908a851b260976ce898a2a3
ISSN 1466-8033
IngestDate Fri Jul 11 10:53:52 EDT 2025
Tue Jul 01 02:20:43 EDT 2025
Thu Apr 24 23:00:15 EDT 2025
Tue Dec 17 20:59:51 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 25
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c323t-e1272ecbdfa463916e16cc0f5fe2c9017052d62bac908a851b260976ce898a2a3
Notes 10.1039/c6ce00380j
Electronic supplementary information (ESI) available. See DOI
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PQID 1825516229
PQPubID 23500
PageCount 11
ParticipantIDs rsc_primary_c6ce00380j
crossref_citationtrail_10_1039_C6CE00380J
crossref_primary_10_1039_C6CE00380J
proquest_miscellaneous_1825516229
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-01-01
PublicationDateYYYYMMDD 2016-01-01
PublicationDate_xml – month: 01
  year: 2016
  text: 2016-01-01
  day: 01
PublicationDecade 2010
PublicationTitle CrystEngComm
PublicationYear 2016
References Brittain (C6CE00380J-(cit12)/*[position()=1]) 2013; 102
ter Horst (C6CE00380J-(cit37)/*[position()=1]) 2009; 9
Vishweshwar (C6CE00380J-(cit5)/*[position()=1]) 2006; 95
Habgood (C6CE00380J-(cit34)/*[position()=1]) 2010; 10
Eccles (C6CE00380J-(cit44)/*[position()=1]) 2011; 13
Cherukuvada (C6CE00380J-(cit25)/*[position()=1]) 2012; 14
Della Gatta (C6CE00380J-(cit48)/*[position()=1]) 2006; 78
Évora (C6CE00380J-(cit31)/*[position()=1]) 2012
Bond (C6CE00380J-(cit3)/*[position()=1]) 2007; 9
Brittain (C6CE00380J-(cit6)/*[position()=1]) 2013; 102
Nigond (C6CE00380J-(cit24)/*[position()=1]) 1995; 30
Corvis (C6CE00380J-(cit51)/*[position()=1]) 2010; 114
Duggirala (C6CE00380J-(cit21)/*[position()=1]) 2016; 52
Chadwick (C6CE00380J-(cit36)/*[position()=1]) 2009; 11
Cassidy (C6CE00380J-(cit57)/*[position()=1]) 1999
Castaneda (C6CE00380J-(cit58)/*[position()=1]) 2003; 660
Kulkarni (C6CE00380J-(cit46)/*[position()=1]) 2012; 48
Hadzi (C6CE00380J-(cit59)/*[position()=1]) 1966
Juncher (C6CE00380J-(cit13)/*[position()=1]) 1957; 4
Evora (C6CE00380J-(cit41)/*[position()=1]) 2012; 14
Dunitz (C6CE00380J-(cit4)/*[position()=1]) 2003; 5
Choquesillo-Lazarte (C6CE00380J-(cit61)/*[position()=1]) 2011; 44
Evora (C6CE00380J-(cit11)/*[position()=1]) 2011; 11
Meanwell (C6CE00380J-(cit10)/*[position()=1]) 2008; vol. 43
Prigogine (C6CE00380J-(cit56)/*[position()=1]) 1954
Sabbah (C6CE00380J-(cit47)/*[position()=1]) 1999; 331
Cherukuvada (C6CE00380J-(cit26)/*[position()=1]) 2014; 50
Dorn (C6CE00380J-(cit23)/*[position()=1]) 2006; 59
Almarsson (C6CE00380J-(cit14)/*[position()=1]) 2004
Chen (C6CE00380J-(cit19)/*[position()=1]) 2007
Lipinski (C6CE00380J-(cit15)/*[position()=1]) 2000; 44
Aakeroy (C6CE00380J-(cit43)/*[position()=1]) 2003; 3
Seaton (C6CE00380J-(cit29)/*[position()=1]) 2009; 9
Kang (C6CE00380J-(cit52)/*[position()=1]) 2000; 206
Chiarella (C6CE00380J-(cit35)/*[position()=1]) 2007; 7
Hohne (C6CE00380J-(cit53)/*[position()=1]) 1990; 160
Bak (C6CE00380J-(cit17)/*[position()=1]) 2008; 97
Wang (C6CE00380J-(cit32)/*[position()=1]) 2013; 17
Berk (C6CE00380J-(cit28)/*[position()=1]) 2012; 19
Wouters (C6CE00380J-(cit9)/*[position()=1]) 2012
Bucar (C6CE00380J-(cit8)/*[position()=1]) 2013; 15
Lemke (C6CE00380J-(cit20)/*[position()=1]) 2008
Takagi (C6CE00380J-(cit22)/*[position()=1]) 2006; 3
Takano (C6CE00380J-(cit42)/*[position()=1]) 1966; 21
Desiraju (C6CE00380J-(cit2)/*[position()=1]) 2003; 5
Landenberger (C6CE00380J-(cit7)/*[position()=1]) 2013; 52
Castro (C6CE00380J-(cit39)/*[position()=1]) 2011; 11
Li (C6CE00380J-(cit45)/*[position()=1]) 2011; 47
Évora (C6CE00380J-(cit30)/*[position()=1]) 2014
Holan (C6CE00380J-(cit38)/*[position()=1]) 2014; 63
Cross (C6CE00380J-(cit40)/*[position()=1]) 2003; 3
Chan (C6CE00380J-(cit33)/*[position()=1]) 2014; 16
Gallis (C6CE00380J-(cit54)/*[position()=1]) 1996; 274
Stanton (C6CE00380J-(cit16)/*[position()=1]) 2008; 8
McNamara (C6CE00380J-(cit18)/*[position()=1]) 2006; 23
Le Minh (C6CE00380J-(cit55)/*[position()=1]) 2010; 99
Mukherjee (C6CE00380J-(cit60)/*[position()=1]) 2013; 15
References_xml – issn: 2012
  publication-title: Pharmaceutical Salts and Co-crystals
  doi: Wouters Quéré
– issn: 2008
  issue: vol. 43
  end-page: p 373-404
  publication-title: Annu. Rep. Med. Chem.
  doi: Meanwell
– issn: 1954
  publication-title: Chemical Thermodynamics
  doi: Prigogine Defay
– issn: 2012
  publication-title: Binary solid-liquid phase diagrams of diflunisal and pyridinecarboxamides
  doi: Évora Castro Maria Rosado Silva Canotilho Eusébio
– issn: 2008
  publication-title: Foye's Principles of Medicinal Chemistry
  doi: Lemke Williams Roche Zito
– volume-title: Pharmaceutical Salts and Co-crystals
  year: 2012
  ident: C6CE00380J-(cit9)/*[position()=1]
– start-page: 439
  year: 1966
  ident: C6CE00380J-(cit59)/*[position()=1]
  publication-title: J. Chem. Soc. A
  doi: 10.1039/J19660000439
– volume: 8
  start-page: 3856
  year: 2008
  ident: C6CE00380J-(cit16)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg800173d
– volume: 16
  start-page: 4365
  year: 2014
  ident: C6CE00380J-(cit33)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/C4CE00265B
– volume: 97
  start-page: 3942
  year: 2008
  ident: C6CE00380J-(cit17)/*[position()=1]
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.21280
– volume: 21
  start-page: 514
  year: 1966
  ident: C6CE00380J-(cit42)/*[position()=1]
  publication-title: Acta Crystallogr.
  doi: 10.1107/S0365110X66003396
– volume: 660
  start-page: 25
  year: 2003
  ident: C6CE00380J-(cit58)/*[position()=1]
  publication-title: J. Mol. Struct.
  doi: 10.1016/j.molstruc.2003.07.010
– volume: 3
  start-page: 631
  year: 2006
  ident: C6CE00380J-(cit22)/*[position()=1]
  publication-title: Mol. Pharmaceutics
  doi: 10.1021/mp0600182
– volume: 11
  start-page: 412
  year: 2009
  ident: C6CE00380J-(cit36)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/b818268j
– volume: 9
  start-page: 47
  year: 2009
  ident: C6CE00380J-(cit29)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg701024c
– volume: 14
  start-page: 8649
  year: 2012
  ident: C6CE00380J-(cit41)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/c2ce26244d
– volume: 5
  start-page: 466
  year: 2003
  ident: C6CE00380J-(cit2)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/b313552g
– volume-title: Chemical Thermodynamics
  year: 1954
  ident: C6CE00380J-(cit56)/*[position()=1]
– volume: 52
  start-page: 640
  year: 2016
  ident: C6CE00380J-(cit21)/*[position()=1]
  publication-title: Chem. Commun.
  doi: 10.1039/C5CC08216A
– start-page: 1889
  year: 2004
  ident: C6CE00380J-(cit14)/*[position()=1]
  publication-title: Chem. Commun.
  doi: 10.1039/b402150a
– volume: 47
  start-page: 1530
  year: 2011
  ident: C6CE00380J-(cit45)/*[position()=1]
  publication-title: Chem. Commun.
  doi: 10.1039/C0CC04117C
– volume: 44
  start-page: 172
  year: 2011
  ident: C6CE00380J-(cit61)/*[position()=1]
  publication-title: J. Appl. Crystallogr.
  doi: 10.1107/S0021889810054725
– volume-title: Binary solid–liquid phase diagrams of diflunisal and pyridinecarboxamides
  year: 2012
  ident: C6CE00380J-(cit31)/*[position()=1]
– start-page: 419
  year: 2007
  ident: C6CE00380J-(cit19)/*[position()=1]
  publication-title: Chem. Commun.
  doi: 10.1039/B612353H
– volume: vol. 43
  volume-title: Annu. Rep. Med. Chem.
  year: 2008
  ident: C6CE00380J-(cit10)/*[position()=1]
– volume: 78
  start-page: 1455
  year: 2006
  ident: C6CE00380J-(cit48)/*[position()=1]
  publication-title: Pure Appl. Chem.
  doi: 10.1351/pac200678071455
– volume: 11
  start-page: 5396
  year: 2011
  ident: C6CE00380J-(cit39)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg2009946
– volume: 48
  start-page: 4983
  year: 2012
  ident: C6CE00380J-(cit46)/*[position()=1]
  publication-title: Chem. Commun.
  doi: 10.1039/c2cc18025a
– volume: 17
  start-page: 1413
  year: 2013
  ident: C6CE00380J-(cit32)/*[position()=1]
  publication-title: Org. Process Res. Dev.
  doi: 10.1021/op400182k
– volume-title: Foye's Principles of Medicinal Chemistry
  year: 2008
  ident: C6CE00380J-(cit20)/*[position()=1]
– volume: 44
  start-page: 235
  year: 2000
  ident: C6CE00380J-(cit15)/*[position()=1]
  publication-title: J. Pharmacol. Toxicol. Methods
  doi: 10.1016/S1056-8719(00)00107-6
– volume: 102
  start-page: 311
  year: 2013
  ident: C6CE00380J-(cit12)/*[position()=1]
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.23402
– volume: 3
  start-page: 159
  year: 2003
  ident: C6CE00380J-(cit43)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg025593z
– volume: 52
  start-page: 6468
  year: 2013
  ident: C6CE00380J-(cit7)/*[position()=1]
  publication-title: Angew. Chem., Int. Ed.
  doi: 10.1002/anie.201302814
– volume: 10
  start-page: 903
  year: 2010
  ident: C6CE00380J-(cit34)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg901230b
– volume: 99
  start-page: 4084
  year: 2010
  ident: C6CE00380J-(cit55)/*[position()=1]
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.22234
– volume: 15
  start-page: 4640
  year: 2013
  ident: C6CE00380J-(cit60)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/c3ce40286j
– volume: 5
  start-page: 506
  year: 2003
  ident: C6CE00380J-(cit4)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/b315687g
– volume: 30
  start-page: 2075
  year: 1995
  ident: C6CE00380J-(cit24)/*[position()=1]
  publication-title: Sep. Sci. Technol.
  doi: 10.1080/01496399508010394
– volume: 19
  start-page: 37
  year: 2012
  ident: C6CE00380J-(cit28)/*[position()=1]
  publication-title: Amyloid
  doi: 10.3109/13506129.2012.678509
– volume: 3
  start-page: 151
  year: 2003
  ident: C6CE00380J-(cit40)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg025589n
– volume: 9
  start-page: 1531
  year: 2009
  ident: C6CE00380J-(cit37)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg801200h
– volume: 206
  start-page: 35
  year: 2000
  ident: C6CE00380J-(cit52)/*[position()=1]
  publication-title: Int. J. Pharm.
  doi: 10.1016/S0378-5173(00)00505-6
– volume: 4
  start-page: 497
  year: 1957
  ident: C6CE00380J-(cit13)/*[position()=1]
  publication-title: Antibiot. Med. Clin. Ther.
– volume: 114
  start-page: 5420
  year: 2010
  ident: C6CE00380J-(cit51)/*[position()=1]
  publication-title: J. Phys. Chem. B
  doi: 10.1021/jp101303j
– volume: 331
  start-page: 93
  year: 1999
  ident: C6CE00380J-(cit47)/*[position()=1]
  publication-title: Acta
– volume: 59
  start-page: 22
  year: 2006
  ident: C6CE00380J-(cit23)/*[position()=1]
  publication-title: Aust. J. Chem.
  doi: 10.1071/CH05270
– volume: 23
  start-page: 1888
  year: 2006
  ident: C6CE00380J-(cit18)/*[position()=1]
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-006-9032-3
– volume: 7
  start-page: 1223
  year: 2007
  ident: C6CE00380J-(cit35)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg070218y
– volume: 9
  start-page: 833
  year: 2007
  ident: C6CE00380J-(cit3)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/b708112j
– volume: 11
  start-page: 4780
  year: 2011
  ident: C6CE00380J-(cit11)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg200288b
– volume: 63
  start-page: 124
  year: 2014
  ident: C6CE00380J-(cit38)/*[position()=1]
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2014.06.017
– volume: 50
  start-page: 906
  year: 2014
  ident: C6CE00380J-(cit26)/*[position()=1]
  publication-title: Chem. Commun.
  doi: 10.1039/C3CC47521B
– volume: 102
  start-page: 311
  year: 2013
  ident: C6CE00380J-(cit6)/*[position()=1]
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.23402
– start-page: 68
  year: 2014
  ident: C6CE00380J-(cit30)/*[position()=1]
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2014.02.048
– volume: 13
  start-page: 6923
  year: 2011
  ident: C6CE00380J-(cit44)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/c1ce06320k
– start-page: 635
  year: 1999
  ident: C6CE00380J-(cit57)/*[position()=1]
  publication-title: J. Chem. Soc., Perkin Trans. 2
  doi: 10.1039/a806387g
– volume: 15
  start-page: 6289
  year: 2013
  ident: C6CE00380J-(cit8)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/c3ce41013g
– volume: 14
  start-page: 2579
  year: 2012
  ident: C6CE00380J-(cit25)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/c2ce06391c
– volume: 160
  start-page: 1
  year: 1990
  ident: C6CE00380J-(cit53)/*[position()=1]
  publication-title: Thermochim. Acta
  doi: 10.1016/0040-6031(90)80235-Q
– volume: 274
  start-page: 223
  year: 1996
  ident: C6CE00380J-(cit54)/*[position()=1]
  publication-title: Thermochim. Acta
  doi: 10.1016/0040-6031(95)02717-3
– volume: 95
  start-page: 499
  year: 2006
  ident: C6CE00380J-(cit5)/*[position()=1]
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.20578
SSID ssj0014110
Score 2.2154787
Snippet Diflunisal is an anti-inflammatory, non-steroidal drug, class II of the Biopharmaceutical Classification System, which has recently been the subject of renewed...
SourceID proquest
crossref
rsc
SourceType Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 4749
SubjectTerms Drugs
Formations
Ingredients
Isomers
Pharmaceuticals
Phase diagrams
Therapy
Thermodynamics
Title Co-crystals of diflunisal and isomeric pyridinecarboxamides - a thermodynamics and crystal engineering contribution
URI https://www.proquest.com/docview/1825516229
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nj9MwELW63QscEF8rygIygguKUhrbSZNjiYqWFQUJutLeIsdxUFAbr5J0l-XXM47zVVEk4BK1tuND3pNnxuN5Rui166cMAjZhz4Sf2ix1Ajt2nNj2uYzBYEl3HugC59Un7-yCnV-6l6PRzbC6pIqn4ufBupL_QRXaAFddJfsPyHaTQgP8BnzhCQjD868wDpUtilvw74wEcpKlmzo7bcr_s1KZg_JXt0UGJkoKXsTqB99miSwt2-La6Sy2KjGX0hux5mY-S_Y6heY4e3Mv1tCZDfXYZf5NF5m0wOnEux9cq4I30gS64R3NM2V9nlrdTnPIy8pU2HwBlhSJshbTvihiBQF8_f5aFrLk1mran2v8mm2u6z7dyLdqb9_CGe5bSLPWMk9rIRsdjN8X411bEt0srWxutE0bM611Cg-agBnVCqrCE1JnPWffe0PXHT_sO4_QMZmD0zVGx4vl-sPHLgHFwC1q1Wxp8LZ_Y99_6YOSo6K9Mab2TNb30b0mpMALw48HaCTzh-juQGjyESoHTMEqxT1TMICOW6bgQ0zBNuZ4nyn1S818eMAUPGTKY3TxfrkOz-zmug1bUEIrWzpkTqSIk5QzT9djS8cTYpa6qSQiqHWXSOKRmMMfn4OnHkMsDN6skH7gc8LpCRrnKpdPEGbQmJBUgPFi4I-7gUwpAOYlDuUJm9EJetN-xEg0WvT6SpRNVJ-JoEEUeuGy_uDnE_SqG3tlFFgOjnrZYhHBAqmzXjyXaldGEEDrZDAhwQSdAEjdJD2mT__UcYru9NR9hsZVsZPPwQmt4hcNYX4Bf-aNNw
linkProvider Royal Society of Chemistry
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Co-crystals+of+diflunisal+and+isomeric+pyridinecarboxamides+-+a+thermodynamics+and+crystal+engineering+contribution&rft.jtitle=CrystEngComm&rft.au=%C3%89vora%2C+Ant%C3%B3nio+O.+L&rft.au=Castro%2C+Ricardo+A.+E&rft.au=Maria%2C+Teresa+M.+R&rft.au=Silva%2C+M.+Ramos&rft.date=2016-01-01&rft.eissn=1466-8033&rft.volume=18&rft.issue=25&rft.spage=4749&rft.epage=4759&rft_id=info:doi/10.1039%2Fc6ce00380j&rft.externalDocID=c6ce00380j
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1466-8033&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1466-8033&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1466-8033&client=summon